Tissue microarray analysis reveals prognostic significance of syndecan‐1 expression in prostate cancer

Zellweger, Tobias; Ninck, Christoph; Mirlacher, Martina; Annefeld, Matthias; Glass, Andrew G.; Gasser, Thomas C.; Mihatsch, Michael J.; Gelmann, Edward P.; Bubendorf, Lukas

doi:10.1002/pros.10209

Cited by 119 publications

(156 citation statements)

References 43 publications

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…Few studies that have analyzed prediction of PCa-specific death, 39,46 -51 and even fewer have attempted to identify biomarkers of PCa-specific death. [52][53][54][55] The study reported here was possible because of our unique resources, including a large tissue bank and database with extensive follow-up clinical data for Ͼ15 years. Unlike most other cancers, PCa-specific death continues up to the 20th year of follow-up.…”

Section: Discussionmentioning

confidence: 99%

Determining Prostate Cancer-Specific Death through Quantification of Stromogenic Carcinoma Area in Prostatectomy Specimens

Ayala

Müezzínoğlu

Hammerich

et al. 2011

The American Journal of Pathology

View full text Add to dashboard Cite

We previously reported that reactive stroma grading in prostate cancer (PCa) is predictive of biochemical recurrence in prostatectomies and biopsies. In this study, we tested whether quantifying the percentage of reactive stromal grade 3 (RSG 3; stromogenic carcinoma pattern) in the entire tumor is predictive of PCa-specific death. Whole-mount prostatectomies operated by a single surgeon obtained between 1983 and 1998 were reviewed. Reactive stroma was evaluated as described previously, and areas of RSG 3 in the entire tumor were registered as percentages of total tumor. Statistical analysis was performed using Spearman, Kaplan-Meier, and Cox analyses. In all, 872 cases were Prostate cancer (PCa) remains the most common malignancy affecting men and is the second-leading cause of cancer-related death of men in the United States. 1,2 The most accepted and internationally used histological classification to predict the behavior of PCa is the Gleason scoring system. 3-7 Tools such as the Kattan nomogram or the Partin tables combine predictive information to optimize the prediction of time to biochemical recurrence (BCR). 8 -11 However, all of these histological parameters examine the epithelial component of the cancer, and not the interaction between the tumor and the host.The most common histological interaction between the tumor and the native host stroma in many tumors is desmoplasia, or reactive stroma (RS). Reactive stroma in PCa was described in our previous studies and characterized at the phenotypic, 12-15 morphological, 16,17 and genomic levels. 18 We immunophenotyped RS as cells coexpressing vimentin and smooth muscle ␣-actin, with loss of terminal muscle differentiation markers such as desmin and/or calponin. Other studies described RS as a mixture of fibroblasts, myofibroblasts, endothelial cells, and immune cells in breast cancer. 19 -21 We recently demonstrated that RS is promising as a new marker to predict a patient's time to progression in PCa, using both biopsies and tissue microarrays from radical prostatectomy specimens. [12][13][14] To determine whether RS carries predictive information, we charac-

show abstract

Section: Discussionmentioning

confidence: 99%

Determining Prostate Cancer-Specific Death through Quantification of Stromogenic Carcinoma Area in Prostatectomy Specimens

Ayala

Müezzínoğlu

Hammerich

et al. 2011

The American Journal of Pathology

View full text Add to dashboard Cite

show abstract

“…Several studies investigated syndecans in prostate cancer, but were mostly focused on SDC1, [18][19][20][21] and only one addressed expression of SDC2. 16 Contreras et al 16 found SDC2 to be expressed in normal prostate tissue, BPH, PIN, and prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

“…We applied a scanning system similar to that used in earlier studies of syndecan-1 (SDC1) expression in prostate cancer, in which at least moderate staining intensity was required in 410% of tumour cells to define SDC2 overexpression. 18,19 All samples were examined independently by three observers (AD, BK, and DT), and any difference was resolved by a joint review.…”

Section: Methodsmentioning

confidence: 99%

Expression and prognostic role of syndecan-2 in prostate cancer

Popović

Demirović

Spajić

et al. 2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Syndecans are a four-member family of transmembrane heparan sulphate proteoglycans that have different functions in cell signalling, adhesion, cytoskeleton organization, migration, proliferation, and angiogenesis. Several studies investigated the role of syndecan-2 (SDC2) in different carcinomas; however, only one being focused on SDC2 in prostate cancer. SDC2 expression and relationship with established prognostic features were assessed in a cohort of 86 patients treated with radical prostatectomy for clinically localized prostate adenocarcinoma. SDC2 expression was present in the majority of prostate cancers and absent in only 11.6% of cases. SDC2 expression was also recorded in cells of prostatic intraepithelial neoplasia, whereas normal prostatic epithelial tissue and stroma did not express SDC2. SDC2 overexpression in prostate cancer was significantly associated with established features indicative of worse prognosis such as higher preoperative PSA (P ¼ 0.011), higher Gleason score (Po0.001), positive surgical margins (Po0.003), and extraprostatic extension of disease (Po0.003). Moreover, expression of SDC2 was also associated with biochemical disease progression on univariate analysis (Po0.001). Study results supported the potential role of SDC2 in prostatic carcinogenesis and cancer progression. Moreover, SDC2 could serve as an additional prognostic marker that might help in further stratifying the risk of disease progression in patients with prostate cancer.

show abstract

“…Localisation patterns were defined as membranous or cytoplasmic according to previous reports. [8][9][10]15 Intensity was scored as weak (1/111), moderate (11/111) or strong (111/111). The proportion of positive cells was evaluated as negative, ,40%, 40-80% or .80%.…”

Section: Evaluation Of Immunostainingmentioning

confidence: 99%

“…8 In addition, the overexpression of syndecan-1 was associated with a high Gleason score and a poor clinical outcome. 9 Recently, Shariat et al 10 showed that the expression of syndecan-1 was directly correlated with the Gleason score and associated with a high risk of PSA progression after 1 surgery. Nevertheless, the mechanisms involved remain largely unclear, and these differing results need to be addressed.…”

Section: Introductionmentioning

confidence: 99%

Altered expression patterns of syndecan-1 and -2 predict biochemical recurrence in prostate cancer

Ledezma¹,

Cifuentes²,

M³

et al. 2011

Asian J Androl

View full text Add to dashboard Cite

The clinical features of prostate cancer do not provide an accurate determination of patients undergoing biochemical relapse and are therefore not suitable as indicators of prognosis for recurrence. New molecular markers are needed for proper pre-treatment risk stratification of patients. Our aim was to assess the value of altered expression of syndecan-1 and -2 as a marker for predicting biochemical relapse in patients with clinically localized prostate cancer treated by radical prostatectomy. The expression of syndecan-1 and -2 was examined by immunohistochemical staining in a series of 60 paraffin-embedded tissue samples from patients with localized prostate cancer. Ten specimens from patients with benign prostatic hyperplasia were used as non-malignant controls. Semiquantitative analysis was performed to evaluate the staining patterns. To investigate the prognostic value, Kaplan-Meier survival curves were performed and compared by a log-rank test. In benign samples, syndecan-1 was expressed in basal and secretory epithelial cells with basolateral membrane localisation, whereas syndecan-2 was expressed preferentially in basal cells. In prostate cancer samples, the expression patterns of both syndecans shifted to granular-cytoplasmic localisation. Survival analysis showed a significant difference (P,0.05) between normal and altered expression of syndecan-1 and -2 in free prostate-specific antigen recurrence survival curves. These data suggest that the expression of syndecan-1 and -2 can be used as a prognostic marker for patients with clinically localized prostate cancer, improving the prostate-specific antigen recurrence risk stratification.

show abstract

Tissue microarray analysis reveals prognostic significance of syndecan‐1 expression in prostate cancer

Cited by 119 publications

References 43 publications

Determining Prostate Cancer-Specific Death through Quantification of Stromogenic Carcinoma Area in Prostatectomy Specimens

Determining Prostate Cancer-Specific Death through Quantification of Stromogenic Carcinoma Area in Prostatectomy Specimens

Expression and prognostic role of syndecan-2 in prostate cancer

Altered expression patterns of syndecan-1 and -2 predict biochemical recurrence in prostate cancer

Contact Info

Product

Resources

About